A Phase 1/2 interventional study of ARV-110 in Prostate Cancer Metastatic, sponsored by Arvinas Inc.. Completed at 54 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Arvinas Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.
Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 436th largest by enrollment of the 3,024 interventional ones that give a count, is one of 160 that started in 2019, is one of 284 in phase 1/2, and was the 2,380th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–80 · Men only
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 50–75 · Men only · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,597 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 899 · Phase 2 1,384 · Phase 3 321 · Phase 4 50
First in 1988; this study’s year is marked. 160 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 48 across the 3,024 interventional studies, 158 across the 478 observational. Of the 2,360 that completed or were terminated, 997 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
922 of 3,597 have an industry lead sponsor. The 10 most frequent:
Arvinas Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Arvinas Inc. has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
334 of the studies in Prostatic Neoplasms with a site in United States that are under way reach primary completion within a year, 24 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06970847Phase 3Clarity Pharmaceuticals Ltd64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | 2026-12-31 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT07427043Phase 3Brigham and Women's HospitalRobotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) | 2026-12-31 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
Add all 334 to your calendar (.ics) → With an account.
Among the 3,597 studies in Prostatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A:
Part B:
Part B - Phase 2 Expansion Cohort Subgroup 4
Exclusion Criteria:
Part A:
Part B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Oral tablet(s), once or twice daily in 28 day cycles Part B: Oral tablet(s), once or twice daily in 28 day cycles
Drug: ARV-110
Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A
Part A: Incidence of Dose Limiting Toxicities of ARV-110
First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug
Time frame: 28 Days
Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-110
Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug.
Time frame: 28 Days
Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-110
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.
Time frame: 28 Days
Part B: Measurement of PSA response rate per PCWG3 accessing anti-tumor activity of ARV-110
PSA response rate per PCWG3.
Time frame: 12 Weeks
Part B: Measurement of overall RECIST response rate accessing the anti-tumor activity of ARV-110
Overall RECIST response rate in patients with measurable disease at baseline.
Time frame: 12 Weeks
Part B: To evaluate the clinical anti-tumor activity of ARV-110 in patients with mCRPC
To evaluate the clinical anti-tumor activity (PSA response rate per PCWG3, Overall RECIST RR, rPFS, and PFS) of ARV-110 in patients with mCRPC in different subgroups of patients with mCRPC with predefined tumor genomic and molecular profiles or based on prior therapy.
Time frame: 12 Weeks
Part A: Anti-tumor activity based on the overall PSA response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.
The anti-tumor activity of ARV-110 will be assessed by evaluating the overall PSA response per PCWG3.
Time frame: 12 Weeks
Part A: Anti-tumor activity based on the overall RECIST response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.
The anti-tumor activity of ARV-110 will be assessed by evaluating the overall RECIST response rate.
Time frame: 12 Weeks
Part A: Anti-tumor activity based on the progression free survival in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.
The anti-tumor activity of ARV-110 will be assessed by evaluating the time to event progression free survival.
Time frame: 12 Weeks
Part A: Anti-tumor activity based on the duration of response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.
The anti-tumor activity of ARV-110 will be assessed by evaluating the duration of response.
Time frame: 12 Weeks
Part A: Anti-tumor activity based on the time to progression in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.
The anti-tumor activity of ARV-110 will be assessed by evaluating the time to progression.
Time frame: 12 Weeks
Part A: Anti-tumor activity based on the overall survival in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.
The anti-tumor activity of ARV-110 will be assessed by evaluating the overall survival.
Time frame: 12 Weeks
Part A: Concentration-time curve (AUC) for single and multiple dose of ARV-110
PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC).
Time frame: 28 Days
Part A: Maximum concentration (Cmax) for single and multiple dose of ARV-110
PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter maximum concentration (Cmax).
Time frame: 28 Days
Part A: Minimum concentration (Cmin) for single and multiple dose of ARV-110
PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter minimum concentration (Cmin).
Time frame: 28 Days
Part A: Time to maximum concentration (Tmax) for single and multiple dose of ARV-110
PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)
Time frame: 28 Days
Part B: Concentration-time curve (AUC) for single and multiple dose of ARV-110
PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC).
Time frame: 28 Days
Part B: Maximum concentration (Cmax) for single and multiple dose of ARV-110
PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter maximum concentration (Cmax).
Time frame: 28 Days
Part B: Minimum concentration (Cmin) for single and multiple dose of ARV-110
PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter minimum concentration (Cmin).
Time frame: 28 Days
Part B: Time to maximum concentration (Tmax) for single and multiple dose of ARV-110
PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)
Time frame: 28 Days
Part B: Duration of response
From the date of first confirmed best overall response of CR or PR to the date of first progression per RECIST 1.1 or PCWG3, or death due to any cause without evidence of radiographic progression, whichever occurs first.
Time frame: 12 Weeks
Part B: Overall survival
Time interval from the date of first ARV-110 dose to the date of death due to any cause.
Time frame: 12 Weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2019 to primary completion in Apr 2024, 61 months.
Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's 61 months is above that.
Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arvinas Inc.